AstraZeneca's Antiplatelet Agent Brilinta Superior To Plavix In Phase III Trial

Importantly for AstraZeneca's antithrombotic portfolio, the company's single Phase III trial for the investigational antiplatelet therapy Brilinta (ticagrelor) was a success - showing superior efficacy over Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) in a head-to-head comparison